Biphasic insulin aspart 30 three times daily is more effective than a twice-daily regimen, without increasing hypoglycemia, in Chinese subjects with type 2 diabetes inadequately controlled on oral antidiabetes drugs

被引:43
|
作者
Yang, Wenying [1 ]
Ji, Qiuhe [2 ]
Zhu, Dalong [3 ]
Yang, Jinkui [4 ]
Chen, Lulu [5 ]
Liu, Zhimin [6 ]
Yu, Demin [7 ]
Yan, Li [8 ]
机构
[1] China Japan Friendship Hosp, Dept Endocrinol, Beijing, Peoples R China
[2] Fourth Mil Med Univ, Xijing Hosp, Dept Endocrinol, Xian 710032, Peoples R China
[3] Nanjing Drum Tower Hosp, Dept Endocrinol, Nanjing, Peoples R China
[4] Beijing Tongren Hosp, Dept Endocrinol, Beijing, Peoples R China
[5] Wuhan Union Hosp, Dept Endocrinol, Wuhan, Peoples R China
[6] Shanghai Changzheng Hosp, Dept Endocrinol, Shanghai, Peoples R China
[7] Tianjin Med Univ, Metab Dis Hosp, Dept Endocrinol, Tianjin, Peoples R China
[8] Zhongshan Univ, Sun Yixian Commemorat Hosp, Dept Endocrinol, Guangzhou, Peoples R China
关键词
D O I
10.2337/dc07-1992
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE - To assess the efficacy and safety of twice- and thrice-daily biphasic insulin aspart 30 (BIAsp 30) in Chinese subjects with type 2 diabetes inadequately controlled with oral antidiabetes drugs (OADs). RESEARCH DESIGN AND METHODS - In this 24-week, multicenter, parallel-group, randomized, treat-to-targeL Study, 321 Chinese insulin-naive subjects with poorly controlled type 2 diabetes (fasting blood glucose >= 7.8 mmol/l and AlC >= 7.5 %) were randomized (1:1) to twice- or thrice-daily (BID and TID groups, respectively) BIAsp 30 without OADs. Initial insulin doses were based on fasting blood glucose at randomization. Insulin dose was adjusted with algorithm-controlled titration to achieve premeal blood glucose of 4.4-6.1 mmol/l. RESULTS - AlC decreased significantly in both groups (BID group -2.48 +/- 0.07%; TID group -2.81 +/- 0.07%). Thrice-daily BIAsp 30 showed superiority in AlC improvement (-0.33% 195% CI -0.53 to -0.131; P < 0.01) and helped more subjects achieve AlC targets < 7% (BID group 51.3% vs. TID group 65.8%; P < 0.01). Thrice-daily BIAsp 30 was more effective in subjects with baseline AlC >= 9% (< 7%: BID group 41.5% vs. TID group 58.3%; P < 0.01), There was no significant difference in rates of overall and nocturnal major and minor hypoglycemia per subject year between groups. No significant differences in weight gain (BID group 3.87 +/- 0.28 kg; TID group 4.09 +/- 0.27 kg) and mean daily insulin doses (BID group 0.82 +/- 0.28 units/kg; TID group 0.86 +/- 0.34 units/kg) were observed. CONCLUSIONS - Twice-and thrice-daily BIAsp 30 were effective in Chinese insulin-naive subjects with poorly controlled type 2 diabetes. Thrice-daily BIAsp 30 offered greater reduction in AlC without increasing risk of hypoglycemia, insulin dose, and weight gain, especially in subjects with AlC >= 9%.
引用
收藏
页码:852 / 856
页数:5
相关论文
共 50 条
  • [1] Thrice-daily biphasic insulin aspart 30 is more effective and as safe as a twice-daily regimen in subjects with type 2 diabetes inadequately controlled with OADs
    Yang, W.
    Ji, Q.
    Zhu, D.
    Yang, J.
    Chen, L.
    Liu, Z.
    Yu, D.
    Yan, L.
    [J]. DIABETOLOGIA, 2007, 50 : S409 - S409
  • [3] Efficacy and safety of three-times-daily versus twice-daily biphasic insulin aspart 30 in patients with type 2 diabetes mellitus inadequately controlled with basal insulin combined with oral antidiabetic drugs
    Yang, Wenying
    Ersoy, Canan
    Wang, Guixia
    Ye, Shandong
    Liu, Jun
    Miao, Heng
    Asirvatham, Arthur
    Werther, Shanti
    Kadu, Priti
    Chow, Francis
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2019, 150 : 158 - 166
  • [4] Effect of sulfonylureas on switching to insulin therapy (twice-daily biphasic insulin aspart 30): Comparison of twice-daily biphasic insulin aspart 30 with or without glimepiride in type 2 diabetic patients poorly controlled with sub-maximal glimepiride
    Ebato, C.
    Shimizu, T.
    Arakawa, M.
    Mita, T.
    Fujitani, Y.
    Watada, H.
    Kawamori, R.
    Hirose, T.
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2009, 86 (01) : 31 - 36
  • [5] A COMPARISON OF TWICE-DAILY BIPHASIC INSULIN ASPART 70/30 AND ONCE-DAILY INSULIN GLARGINE IN PERSONS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED ON BASAL INSULIN AND ORAL THERAPY: A RANDOMIZED, OPEN-LABEL STUDY
    Ligthelm, Robert J.
    Gylvin, Titus
    DeLuzio, Tony
    Raskin, Philip
    [J]. ENDOCRINE PRACTICE, 2011, 17 (01) : 41 - 50
  • [6] Efficacy and safety of twice daily vs. thrice daily injections of biphasic insulin aspart 30 in insulin naive patients with type 2 diabetes inadequately controlled with OADs
    Yang, Wenying
    Ji, Qiuhe
    Zhu, Dalong
    Yang, Jinkui
    Chen, Lulu
    Liu, Zhimin
    Yu, Demin
    Yan, Li
    [J]. DIABETES, 2007, 56 : A546 - A546
  • [7] Once daily initiation with biphasic insulin aspart 30 (BIAsp 30) versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs - a randomized controlled trial
    Franek, E.
    Kalra, S.
    Pesic, M.
    Smahelova, A.
    Thomsen, H.
    Strojek, K.
    [J]. DIABETOLOGIA, 2009, 52 : S93 - S93
  • [8] Adding biphasic insulin aspart 30 once or twice daily is more efficacious than optimizing oral antidiabetic treatment in patients with type 2 diabetes
    Bebakar, W. M. W.
    Chow, C. C.
    Kadir, K. A.
    Suwanwalaikorn, S.
    Vaz, J. A.
    Bech, O. M.
    [J]. DIABETES OBESITY & METABOLISM, 2007, 9 (05): : 724 - 732
  • [9] Subject Titration Twice-Daily Biphasic Insulin Aspart 30 Showed Similar Efficacy without Increasing Hypoglycemia Compared with Investigator Titration in a Randomized Trial
    Liu, Yu
    Wang, Wenhui
    Guo, Lian
    Zhang, Zhenwen
    Li, Quanmin
    Qu, Shen
    Li, Chengjiang
    Ji, Qiuhe
    [J]. DIABETES, 2014, 63 : A234 - A234
  • [10] Insulin degludec/insulin aspart vs biphasic insulin aspart 30 twice daily in Japanese patients with type 2 diabetes: A randomized controlled trial
    Onishi, Yukiko
    Yamada, Kenichi
    Zacho, Jeppe
    Ekelund, Jan
    Iwamoto, Yasuhiko
    [J]. JOURNAL OF DIABETES INVESTIGATION, 2017, 8 (02) : 210 - 217